These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26185319)

  • 1. Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.
    Wedel W; Sofronescu AG
    Am J Clin Pathol; 2015 Aug; 144(2):329-32. PubMed ID: 26185319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of severe aplastic anemia secondary to treatment with lenalidomide for multiple myeloma.
    Dasanu CA; Alexandrescu DT
    Eur J Haematol; 2009 Mar; 82(3):231-4. PubMed ID: 19018868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutrophilic dermatosis complicating lenalidomide therapy.
    Thieu KP; Rosenbach M; Xu X; Kist JM
    J Am Acad Dermatol; 2009 Oct; 61(4):709-10. PubMed ID: 19577327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide.
    Mariz JM; Esteves GV
    Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide and its role in the management of multiple myeloma.
    Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
    Seki JT; Banglawala S; Lentz EM; Reece DE
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
    [No Abstract]   [Full Text] [Related]  

  • 7. Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.
    Walavalkar V; Adey DB; Laszik ZG; Jen KY
    Transplant Proc; 2018 Apr; 50(3):873-876. PubMed ID: 29661456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
    Oehrlein K; Langer C; Sturm I; Pönisch W; Hahn-Ast C; Kuhn S; Weisel KC
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):191-6. PubMed ID: 22341857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
    Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
    Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
    [No Abstract]   [Full Text] [Related]  

  • 11. Possible lenalidomide-induced Stevens-Johnson syndrome during treatment for multiple myeloma.
    Boruah PK; Bolesta S; Shetty SM
    Pharmacotherapy; 2011 Sep; 31(9):925. PubMed ID: 21923596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
    Tannemaat MR; Vries EP; Molendijk WJ; Haan J
    Clin Neurol Neurosurg; 2011 Jul; 113(6):488-9. PubMed ID: 21315504
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
    Morita Y; Shimada T; Yamaguchi T; Rai S; Hirase C; Emoto M; Serizawa K; Taniguchi Y; Ojima M; Tatsumi Y; Ashida T; Matsumura I
    Int J Hematol; 2011 Dec; 94(6):583-4. PubMed ID: 22127558
    [No Abstract]   [Full Text] [Related]  

  • 14. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
    Attal M; Lauwers-Cances V; Marit G; Caillot D; Moreau P; Facon T; Stoppa AM; Hulin C; Benboubker L; Garderet L; Decaux O; Leyvraz S; Vekemans MC; Voillat L; Michallet M; Pegourie B; Dumontet C; Roussel M; Leleu X; Mathiot C; Payen C; Avet-Loiseau H; Harousseau JL;
    N Engl J Med; 2012 May; 366(19):1782-91. PubMed ID: 22571202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multiple myeloma: thalidomide-, bortezomib-, and lenalidomide-induced peripheral neuropathy.
    Koeppen S
    Oncol Res Treat; 2014; 37(9):506-13. PubMed ID: 25231692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of the adverse effects of lenalidomide in multiple myeloma.
    González Rodríguez AP
    Adv Ther; 2011 Mar; 28 Suppl 1():1-10. PubMed ID: 21431626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversible pulmonary toxicity due to lenalidomide.
    Coates S; Barker A; Spurgeon S
    J Oncol Pharm Pract; 2012 Jun; 18(2):284-6. PubMed ID: 21742815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide.
    Kastritis E; Dimopoulos M
    Leuk Lymphoma; 2007 Dec; 48(12):2295-7. PubMed ID: 18066998
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.